Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c

Go back to Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c

Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 10, 2020 7:30 AM EDT

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2020, and provided a corporate update.

We have completed our first full quarter of commercial activities, adapting to the unprecedented challenges of the COVID-19 pandemic, and I am encouraged by CAPLYTAs week over week prescription growth and increasing prescriber base, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.  I am pleased with our... More